Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selpercatinib - Loxo oncology

Drug Profile

Selpercatinib - Loxo oncology

Alternative Names: LOXO 292; LY-3527723; RETEVMOTM; Retsevmo

Latest Information Update: 30 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma
  • Developer Eli Lilly and Company; Loxo Oncology
  • Class Antineoplastics; Aza compounds; Ethers; Nitriles; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Proto oncogene protein c ret inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Pancreatic cancer; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer; Thyroid cancer
  • Phase II Solid tumours
  • Phase I/II CNS cancer

Most Recent Events

  • 21 Jun 2021 Registered for Non-small cell lung cancer (Metastatic disease, In adults) in Canada (PO)
  • 21 Jun 2021 Registered for Thyroid cancer (Late-stage disease, Metastatic disease, In adolescents, In adults, Inoperable/Unresectable) (RET-mutant) in Canada (PO)
  • 21 Jun 2021 Health Canada approved selpercatinib under conditional marketing authorisation for RET fusion positive Thyroid cancer (Late-stage disease, Metastatic disease, In adults) (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top